Gastroenterology Research and Practice / 2016 / Article / Tab 1

Clinical Study

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study

Table 1

Baseline demographics of patients with ulcerative colitis (UC) who achieved remission with prednisolone (PSL) or tacrolimus (TAC) and were retrospectively reviewed.

DemographyPSL group ()TAC group () value

Age (years)42.4 ± 17.543.7 ± 15.6NS
Duration of UC (years)5.6 ± 6.68.7 ± 1.3<0.05
Extent of UC, pancolitis/left-sided colitis48/6/124/16/0NS
Past AZA therapy (yes/no)35/2029/11NS
Clinical activity index (CAI) 11.8 ± 2.613.6 ± 2.8<0.05
Duration of hospital stay (days) 32.5 ± 6.926 ± 10.2<0.05
Total PSL until remission (mg) 702 ± 368706 ± 354NS
Discontinuance of PSL after remission (yes/no)17/3827/13<0.05

Baseline Hb (g/dL) 12.3 ± 2.212.2 ± 2.5NS
Baseline CRP (mg/dL) 3.8 ± 4.32.3 ± 3.3NS

Mayo2.7 ± 0.43.0 ± 0.0<0.05
UCEIS3.4 ± 1.95.1 ± 1.6<0.05
EAI12.3 ± 2.313.8 ± 2.4<0.05

Data are mean ± SD or number of patients.
AZA, azathioprine; CRP, C-reactive protein; EAI, endoscopic activity index; Hb, hemoglobin; NS, not significant; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.